ICON Public (NASDAQ:ICLR) Given “Outperform” Rating at William Blair

ICON Public (NASDAQ:ICLR)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a research report issued to clients and investors on Tuesday,Benzinga reports.

ICLR has been the subject of several other reports. The Goldman Sachs Group lowered their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Barclays cut their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, Truist Financial reiterated a “buy” rating and set a $284.00 price objective (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Trading Down 6.4 %

Shares of ICLR stock traded down $13.87 on Tuesday, reaching $204.12. The company had a trading volume of 717,482 shares, compared to its average volume of 754,097. The stock has a market cap of $16.84 billion, a PE ratio of 22.76, a PEG ratio of 1.54 and a beta of 1.20. The company has a 50-day moving average of $211.31 and a 200-day moving average of $270.81. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 12 month low of $183.38 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the business posted $3.10 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts forecast that ICON Public will post 13.42 earnings per share for the current year.

Institutional Investors Weigh In On ICON Public

Several hedge funds have recently added to or reduced their stakes in the business. Foyston Gordon & Payne Inc bought a new position in shares of ICON Public in the third quarter valued at about $11,672,000. Icon Wealth Advisors LLC lifted its position in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after acquiring an additional 11,840 shares during the last quarter. Sara Bay Financial bought a new stake in shares of ICON Public during the third quarter worth approximately $1,143,000. Whittier Trust Co. increased its stake in shares of ICON Public by 12.3% during the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after purchasing an additional 441 shares during the period. Finally, GAMMA Investing LLC boosted its stake in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.